BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

IntelliPharmaCeutics 

30 Worcester Road

Toronto  Ontario  M9W 5X2  Canada
Phone: 416-798-3001 Fax: 416-798-3007


SEARCH JOBS




Industry
Biotechnology






 Company News
FDA Grants Fast Track Designation For IntelliPharmaCeutics Rexista Oxycodone XR Incorporating PODRAS Technology 5/26/2015 6:38:03 AM
IntelliPharmaCeutics Buys Property That Houses R&D & Office in Toronto, Ontario 5/26/2015 5:38:28 AM
IntelliPharmaCeutics Intends To Accelerate Its Rexista(TM) Oxycodone XR Development Program On The Basis Of Positive Feedback From The FDA 5/21/2015 10:26:01 AM
IntelliPharmaCeutics Reports Director Election Results 4/22/2015 2:01:18 PM
IntelliPharmaCeutics Announces First Quarter 2015 Results 4/15/2015 3:29:17 PM
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015 12:42:39 PM
IntelliPharmaCeutics Announces 2014 Year End Results With A 48% Reduction In Operating Loss 2/23/2015 7:55:51 AM
IntelliPharmaCeutics Reports The Signing Of An Exclusive Licensing And Manufacturing Agreement With TEVA Pharmaceuticals USA (TEVA) For An Extended Release Oral Drug Product Candidate 2/2/2015 7:54:49 AM
IntelliPharmaCeutics Notes Launch Of 5mg Strength Of Focalin XR(R) Generic By Teva Pharmaceutical Industries Limited (TEVA) 11/20/2014 10:33:07 AM
IntelliPharmaCeutics Reports That The FDA Has Given Its Toronto Manufacturing Facility An "Acceptable" Classification 10/27/2014 7:48:06 AM
12345678910